Latest news
Cancer patients are living longer, but pain management has not advanced in tandem. Drug development has stalled due to high risks, and while opioids are effective, they face supply shortages, insurance restrictions, and inadequate physician training. Patients, doctors, and researchers call for more innovative therapies and systemic reforms.
After HHS Secretary Robert F. Kennedy Jr. removed the COVID-19 shot from the CDC's vaccine schedule for healthy children and the FDA limited booster shots, vaccine access has diverged sharply between states. Some patients, like Jennifer O. in Louisiana, are driving hours to neighboring states to find vaccines for their children. Providers report confusion and chaos as they try to obtain accurate guidance, with some states preserving access through executive orders while others restrict it. Experts warn this fragmentation could foreshadow broader disparities in U.S. healthcare policy, where access increasingly depends on where patients live.
There is a clear divergence among U.S. states in COVID-19 vaccine access, with some states restricting vaccinations while others strive to ensure supply, raising concerns in the medical community about the fragmentation of public health policies.
Targeted protein degradation, a field that began with a foundational 2001 paper on PROTACs, is gaining momentum. Arvinas and Pfizer have filed for FDA approval of vepdegestrant, which would be the first approved PROTAC drug if cleared. Kymera Therapeutics and others are advancing degraders that could reach previously undruggable targets, attracting partnerships from large pharmaceutical companies like Roche, Novartis, and Sanofi.
The FDA approval of Vertex's Journavx (suzetrigine) in January 2025 marks a watershed moment for non-opioid pain treatments, validating decades of research into sodium ion channels NaV1.8 and NaV1.7. This approval has reignited investor interest in a field once deemed too risky, as evidenced by SiteOne Therapeutics' $100 million fundraising and its pending $1 billion acquisition by Eli Lilly. While Journavx offers a safer alternative to opioids, its efficacy compared to existing drugs remains debated, leaving room for competitors. At least 11 other companies, including Latigo Biotherapeutics, Dogwood Therapeutics, and Newron Pharmaceuticals, are developing their own sodium channel blockers, targeting both acute and chronic pain. With Vertex expanding into chronic pain and others advancing through clinical trials, the landscape for non-opioid pain management is rapidly evolving.
The mass layoffs at the U.S. Department of Health and Human Services (HHS) this month, which affected around 10,000 workers, were chaotic and may have been illegal, according to lawyers and federal employment experts. Employees described entire offices being closed, including some mandated by law, termination letters with incorrect information, and discrepancies in how employees were selected for layoffs. The reduction-in-force (RIF) process typically requires agencies to define competitive areas, assign retention scores based on tenure, veterans' status, and performance, and follow ranking procedures. Experts say HHS appeared to circumvent these rules by closing entire offices without ranking employees, yet not everyone in those offices was let go. Unions and law firms, including the National Treasury Employees Union and Federal Practice Group, are taking action, with plans for grievances and class-action appeals to the Merit Systems Protection Board. Legal challenges may face hurdles due to staffing shortages at the MSPB and an executive order limiting collective bargaining rights.
The mass layoffs implemented by the US Department of Health and Human Services (HHS) this month, due to their chaotic execution and procedural flaws, are considered by legal experts to potentially be illegal. The layoffs affect approximately 10,000 employees, involve the closure of multiple offices including statutory agencies, and termination notices contain erroneous information. Multiple unions and law firms have intervened, planning to challenge the legality of the layoff decisions through internal appeals or class-action lawsuits.
Merck's Keytruda has long dominated cancer immunotherapy, but a new class of bispecific drugs targeting PD-1 and VEGF may offer a better backbone for the next decade. Ivonescimab, developed by Summit Therapeutics and Akeso, cut lung cancer progression risk in half compared to Keytruda in a Phase 3 trial, igniting interest. More than a dozen companies are now developing similar drugs. While proponents see improved response rates and survival, skeptics note ivonescimab hasn't shown overall survival benefit, wasn't tested against Keytruda-chemotherapy, and the trial was conducted only in China. Key questions remain about safety, efficacy, and whether these drugs can truly unseat Keytruda.